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Background: Type 2 diabetes mellitus (T2DM) is a major risk factor for the acquisition of
latent tuberculosis (TB) infection (LTBI) and development of active tuberculosis (ATB),
although the immunological basis for this susceptibility remains poorly characterised.
Innate lymphoid cells (ILCs) immune responses to TB infection in T2DM comorbidity is
anticipated to be reduced. We compared ILC responses (frequency and cytokine
production) among adult patients with LTBI and T2DM to patients (13) with LTBI only
(14), T2DM only (10) and healthy controls (11).
Methods: Using flow cytometry, ILC phenotypes were categorised based on
(Lin−CD127+CD161+) markers into three types: ILC1 (Lin−CD127+CD161+CRTH2-
CD117−); ILC2 (Lin−CD127+CD161+CRTH2+) and ILC3 (Lin−CD127+CD161+
CRTH2−NKp44+/−CD117+). ILC responses were determined using cytokine production
by measuring percentage expression of interferon-gamma (IFN-g) for ILC1, interleukin (IL)-
13 for ILC2, and IL-22 for ILC3. Glycaemic control among T2DM patients was measured
using glycated haemoglobin (HbA1c) levels. Data were analysed using FlowJo version
10.7.1, and GraphPad Prism version 8.3.
Results: Compared to healthy controls, patients with LTBI and T2DM had reduced
frequencies of ILC2 and ILC3 respectively (median (IQR): 0.01 (0.005-0.04) and 0.002
(IQR; 0.002-0.007) and not ILC1 (0.04 (0.02-0.09) as expected. They also had increased
production of IFN-g [median (IQR): 17.1 (5.6-24.9)], but decreased production of IL-13
[19.6 (12.3-35.1)]. We however found that patients with T2DM had lower ILC cytokine
responses in general but more marked for IL-22 production (median (IQR): IFN-g 9.3 (4.8-
22.6); IL-13 22.2 (14.7-39.7); IL-22 0.7 (IQR; 0.1-2.1) p-value 0.02), which highlights the
immune suppression status of T2DM. We also found that poor glycaemic control altered
ILC immune responses.org August 2021 | Volume 12 | Article 7168191
Ssekamatte et al. T2DM, LTBI and ILC Responses
Frontiers in Immunology | www.frontiersin.Conclusion: This study demonstrates that LTBI and T2DM, and T2DM were associated
with slight alterations of ILC immune responses. Poor T2DM control also slightly altered
these ILC immune responses. Further studies are required to assess if these responses
recover after treatment of either TB or T2DM.Keywords: innate lymphoid cells, type 2 diabetes mellitus, tuberculosis, cytokines, hyperglycaemia, HbA1cINTRODUCTION
Tuberculosis (TB) still remains the leading cause of death from a
single infectious agent globally despite advances in care in the
past decade (1). One-third of the population globally is infected
with the bacteria, Mycobacterium tuberculosis (Mtb) that causes
the disease, and an estimated 10% of these are likely to develop
active tuberculosis in their lifetime (1). Comorbidities such as
Type 2 diabetes mellitus (T2DM) are known to influence the
outcome of Mtb infection (1). T2DM patients are more
susceptible to bacterial pathogens including Mtb (2, 3). T2DM
confers a 3-fold increase in the risk of developing active TB in
latent tuberculosis-infected individuals (4). It is associated with
poor TB treatment outcomes including failure, relapse and death
(4). The susceptibility toMtb in T2DM patients is attributable to
several factors including the direct effects of hyperglycaemia and
consequently insulin resistance, and indirectly largely
attributable to the immune-compromised state in this
population (5). Both innate and adaptive immune responses
are dysregulated in people having T2DM, which delays Mtb
clearance (6–9).
Innate lymphoid cells (ILCs) are a novel family of
hematopoietic effectors that play protective functions in innate
immune responses to microorganisms, in lymphoid tissue
formation, in tissue remodelling after the damage inflicted by
injury and homeostasis of stromal tissue cells (10). Innate
lymphoid cells are tissue-resident cells mainly found at
mucosal surfaces of the intestine (11, 12), lungs (13) and in the
skin (14), making them among the first immune cells to react to
pathogens (15). There are three types of ILCs; ILC1s, ILC2s and
ILC3s (16, 17), that have effector-immune functions and are
involved in adipose tissue metabolism (18, 19). ILCs, unlike
adaptive lymphocytes, do not express known rearranged antigen
receptors but do exhibit T-cell-like functional diversity. Hence,
ILC1s, ILC2s and ILC3s are innate counterparts of the TH1 and
TH2 and TH17 subsets (respectively) of helper T cells in the
adaptive immune system (17, 20). ILC1 cells are comprised of
conventional natural killer cells and bona fide non-NK ILC1 (21).
They respond to interleukin (IL)-12, IL-15 and IL-18 and are
defined by their expression of the transcription factor T-bet (for
function and development), and production of a characteristic
type 1 effector cytokine profile, including interferon-gamma
(IFN-g), tumour necrosis factor (TNF) and oxygen radicals
(17, 21–23). IFN-g is a potent macrophage activator, enhances
the phagocytic activity of the macrophages, and is one of the key
cytokines conferring protection against TB (23–25). Type 2 ILCs
respond to tissue-derived alarmins including IL-25 and IL-33
and thymic stromal lymphopoietin (TSLP) (14). They areorg 2characterized by their expression of GATA-3 and produce the
cytokines IL-4, IL-5, IL-9, and IL-13 (13, 26–28) to combat
helminth infection (29), mediate tissue repair (13, 15, 17, 30) and
play roles in thermogenesis (19). Blood ILC1 & ILC2 have been
implicated in TB infection (31). Type 3 ILCs respond to IL-23
and IL-1b, are characterised by their expression of RORgt and
produce cytokines IL-17A and/or IL-22 (32, 33). They mediate
resistance to intestinal infection (12, 34), and control early-stage
TB infection (31). The three groups of ILCs have been implicated
in adipose obesity-induced diabetes (35–38).
We hypothesized that since T2DM is characterised by an
immune-suppressive state, the frequency of ILC subsets and their
secreted cytokines would also be diminished.MATERIALS AND METHODS
Participants
Latent TB infection and/or T2DM participants were enrolled
from October 2017 to March 2018 in the Tuberculosis and
Diabetes (TAD) study, a case-control study assessing the
frequency of ILCs, T and B cells in LTBI and/or T2DM
patients. T2DM patients were newly diagnosed, hence they
were not on DM treatment or TB preventive therapy that
would affect immune function. All participants were enrolled
after providing informed consent and approval by the
institutional review boards including the Higher Degrees
Research and Ethics Committee (HDREC) of the School of
Biomedical Sciences, Makerere University (Reference number;
SBS-531) and Uganda National Council for Science and
Technology (Reference number; HS66ES). All data were
anonymised. For this study, stored peripheral blood
mononuclear cell (PBMC) samples taken 48 from participants
were used, of which 13 were LTBI/T2DM, 14 were T2DM only,
10 were LTBI only, and 11 were healthy controls (HC). T2DM
was diagnosed using the American Diabetes Association (ADA)
criteria based on glycated haemoglobin (HbA1c) levels ≥ 6.5%
(39) and latent TB infection based on positive results for the
immunological test QuantiFERON TB-Gold-Plus (QFT). All
participants were HIV negative.
PBMC Isolation
PBMCs were isolated from participants by density centrifugation
using a Ficoll gradient. Cells were resuspended in cold heat-
inactivated foetal bovine serum (FBS) supplemented with 10%
dimethyl sulfoxide (DMSO), transferred to liquid nitrogen for
long term storage following an overnight incubation in a
controlled freezing container (Mr Frosty™, Nalgene).August 2021 | Volume 12 | Article 716819
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Frozen PBMCs were thawed in R10 (RPMI with 10% FBS, 1%
Pen/Strep, 2 mMGlutamine, 25mMHEPES) at 37°C and counted
manually using a microscope. PBMCs were rinsed and rested in
R10 at 37°C and 5%CO2 for a minimum of 4 hours. PBMCs were
incubated for 6 hours in R10 supplemented with premixed PMA/
Ionomycin (Cell Activation Cocktail without Brefeldin
A, BioLegend) according to the manufacturer’s instructions.
A negative control was also set up using R10 medium without a
stimulant for comparison for each sample. All PBMCs were then
treated with Brefeldin A (5µg/ml, BioLegend) for the last 4 hours
of the culture period for retention of cytokines according to the
manufacturer’s instructions.
Antibodies
The following anti-human antibodies were used for ILC
immunophenotyping: lineage-BV510 (CD3, CD14, CD16,
CD20, CD56; clone OKT3, M5E2, 3G8, HIB19, 2H7, HCD56),
CD127/IL-7Ra-APC (clone A019D5), CD161-PE (clone HP-
3G10), CD117/c-kit-BV650 (clone 104D2), CD294/CRTH2-
APC-Cy7 (clone BM16), and CD336/NKp44- PE-Cy7 (clone
P44-8), all from BioLegend. For intracellular cytokine staining,
the following anti-human antibodies were used: IFN-g-AF488
(clone 4S.B3), IL-13-BV421 (clone JES10-5A2), and IL-22-
PerCPCy5.5 (clone 2G12A41), all from BioLegend.
Staining and Flow Cytometry
PBMCs were washed with 1X PBS then stained with the fixable
viability dye, zombie yellow (BioLegend), for 20 minutes in the
dark at 4°C. Cells were suspended in cell staining buffer
(BioLegend), before labelling with 50µl of the appropriate
surface antibody panel for 30 minutes in the dark at 4°C.
For intracellular cytokine staining, cells were fixed using
fixation buffer (4% paraformaldehyde, BioLegend), then
permeabilized using working strength (1X) intracellular
staining perm wash buffer (BioLegend) according to
manufacturer’s recommendations. Intracellular cytokine
antibodies were prepared in 1X intracellular staining perm
wash buffer, and 50µl of the intracellular antibody panel was
added and incubated for 30 minutes in the dark at 4°C. After
incubation, cells were washed with 1X intracellular staining perm
wash buffer twice and finally resuspended in cell staining buffer.
Cells were acquired using a BD LSRII flow cytometer.
All flow cytometry data were analysed using FlowJo version
10.6 for Windows. Gating was standardised and set using
Fluorescence Minus One (FMO) controls, and compensation
controls to correct for spectral overlap (Figure 1). ILC
frequencies were expressed as percentages of total lymphocytes.
Single live lymphocytes were gated and ILC populations were
identified. The distinct populations of ILCs were defined as: total
ILCs (Lin−CD127+CD161+); ILC1 (Lin−CD127+CD161+
CRTH2−CD117−), ILC2s (Lin−CD127+CD161+CRTH2+), and
ILC3s (Lin−CD127+CD161+CRTH2−NKp44+/−CD117+). Gating
was performed to determine the percentage expression of IFN-g
by ILC1, IL-13 by ILC2, and IL-22 by ILC3. It’s worth noting that
the majority of the NK cells were missed.Frontiers in Immunology | www.frontiersin.org 3ILC Gating Strategy
Statistical Analysis
All statistical analysis was done using GraphPad version 8.3
software. Kruskal Wallis with correction for Dunn’s post hoc test
was done, and Mann-Whitney U tests for group comparisons.
Data were represented as medians and interquartile ranges.
Differences were defined as statistically significant with a P-
value < 0.05 at a 95% confidence level.RESULTS
We then assessed frequencies of total ILCs, ILC1, ILC2, ILC3,
and the cytokine responses of the ILC sub-sets including IFN-g,
IL-13 and IL-22 by flow cytometry on PBMCs from patients with
LTBI and T2DM (n=13), LTBI (n=14), T2DM (n=10) and HC
(n=11) (Table 1).
Phenotypic Analysis of Total ILCs
and ILC Subsets
We assessed the frequencies of total ILCs, ILC1, ILC2, and ILC3,
and the percentage expression of IFN-g, IL-13, and IL-22 by
gated ILC1, ILC2 and ILC3 cells respectively, using flow
cytometry on stored PBMCs from participants with LTBI and
T2DM, LTBI, T2DM, and healthy controls.
The total ILC frequencies were slightly lower in participants
with LTBI and T2DM [median (IQR): 0.06 (0.03-0.15)]
compared to the healthy controls, but this trend was not
statistically supported (Figure 2). In addition, there was no
significant difference from disease controls (LTBI, and T2DM).
The ILC1 frequencies were slightly lower but non-significant in
participants with LTBI [median (IQR): 0.03 (0.02- 0.12)]
compared to the healthy controls. There were also no observed
significant differences with LTBI and T2DM, and T2DM groups.
The ILC2 frequencies were slightly lower but non-significant in
participants with LTBI and T2DM [median (IQR): 0.01 (0.005-
0.04)] compared to the disease (LTBI, and T2DM) and healthy
controls. Similarly, the ILC3 frequencies were slightly lower but
non-significant in participants with LTBI and T2DM [median
(IQR): 0.002 (0.002-0.007)] compared to LTBI and healthy
control groups. ILC3 were slightly higher in the T2DM group
[median (IQR): 0.007 (0.002-0.010)].
Functional Analysis of ILC Subsets
IFN-g production by ILC1 was slightly increased in participants
with LTBI and T2DM [median (IQR): 17.1 (5.6-24.9)] and
slightly decreased in participants with T2DM [median (IQR):
9.3 (4.8-22.6)] (Figure 3). The trend was not different in
comparison to LTBI and healthy controls. IL-13 production by
ILC2 was slightly increased in participants with LTBI [median
(IQR): 25.1 (15.2-33.3)] and slightly decreased in participants
with LTBI and T2DM [median (IQR): 19.6 (12.3-35.1)]. The
trend was not different in comparison to T2DM and healthy
controls. The IL-22 cytokine levels by ILC3 were generally low
but production was markedly decreased in participants with
T2DM [median (IQR): 0.7 (0.1-2.1)] as compared to healthyAugust 2021 | Volume 12 | Article 716819
Ssekamatte et al. T2DM, LTBI and ILC ResponsesFIGURE 1 | Flow cytometry gating strategy used for ILC identification and cytokine production in human peripheral blood. Representative flow cytometric plots for
ILCs in peripheral blood. Numbers in gates (outlined areas) indicate the per cent cell in each. After gating on the time gate, lymphocytes and single cells, distinct ILC
populations were defined as: total ILCs (Lin [CD3/CD14/CD16/CD19/CD20/CD56]−CD127+CD161+); ILC1 (Lin−CD127+CD161+CRTH2-CD117−); ILC2
(Lin−CD127+CD161+CRTH2+); ILC3 (Lin−CD127+CD161+CRTH2+NKp44+/−CD117+). The cytokine expression levels for IL-13 and IFN-g were evaluated using
intracellular cytokine staining. FSC-A, Forward scatter-area; FSC-H, Forward scatter-height; SSC-A, Side scatter-area.TABLE 1 | Characteristics of the study population.
LTBI and T2DM LTBI T2DM HC P Value
(n = 13) (n = 14) (n = 10) (n =11)
Age, years [Median (IQR)] 51 (40-55.5) 42 (38-49) 55 (41.5-57) 34 (22-40) 0.0045
Sex, M/F (n) 5/8 4/10 5/5 3/8 0.662
Occupation 0.521
Businessman/woman 9 (69%) 7 (50%) 3 (34%) 2 (18%)
Skilled labour 3 (23%) 4 (29%) 4 (44%) 5 (46%)
Unskilled labour 1 (8%) 1 (7%) 1 (11%) 2 (18%)
Unemployed 0 (0%) 2 (14%) 1 (11%) 2 (18%)
Religion 0.526
Anglican 3 (23%) 1 (7%) 3 (34%) 2 (18%)
Catholic 2 (15%) 5 (36%) 1 (11%) 2 (18%)
Saved/Pentecostal 1 (8%) 3 (21%) 1 (11%) 0 (0%)
Muslim 7 (54%) 5 (36%) 4 (44%) 7 (64%)
Education 0.386
Primary 7 (54%) 6 (43%) 1 (11%) 4 (36%)
Secondary 6 (46%) 8 (57%) 7 (78%) 6 (55%)
Tertiary 0 (0%) 0 (0%) 1 (11%) 1 (9%)
Alcohol 0.875
Yes 3 (23%) 3 (21%) 3 (33%) 2 (18%)
No 10 (77%) 11 (79%) 6 (67%) 9 (82%)
Smoking 0.189
Never smoked 11 (85%) 14 (100%) 9 (100%) 10 (91%)
Used to but stopped 0 (0%) 0 (0%) 0 (0%) 1 (9%)
Still smoking 2 (15%) 0 (0%) 0 (0%) 0 (0%)
BCG Vaccination (n/%) 0.325
Yes 11 (84.6%) 14 (100%) 9 (90%) 10 (91%)
No 2 (15.38%) 0 (0%) 1 (10%) 1 (9%)
Fasting blood glucose, mmol/L [Median (IQR)] 10.7 (8.85-14.6) 6.2 (5.1-7.7) 12.58 (9.325-23.29) 4.9 (4.4-5.5) <0.0001
Glycated haemoglobin, % [Median (IQR)] 8.4 (6.7-10.1) 4.85 (4-5.75) 8.75 (7.3-10.73) 4.3 (4-5.6) <0.0001Frontiers in Immunology | www.frontiersin.org 4 August 2021 | Volume 12 | Article 716819
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FIGURE 3 | For the production of IFN-g, IL-13, and IL-22; PBMCs were stimulated and cultured for 6 hours with PMA/ionomycin or unstimulated (US) plus Brefeldin
A and stained intracellularly for cytokines. (A) Representative flow cytometry plots showing the production of IFN-g, IL-13 and IL-22 in response to R10 media
(unstimulated) and PMA/ionomycin. (B) Percentage of ILC1, ILC2 and ILC3 cells expressing IFN-g, IL-13 and IL-22 respectively. Data represent medians and
interquartile ranges. The non-parametric Kruskal-Wallis and Mann-Whitney U tests were performed to determine the statistical significance between the medians.
Differences were considered statistically significant at P < 0.05 and 95% confidence level. Non-significant P-values were not shown. Size of groups: LTBI and T2DM
(n = 13), LTBI (n = 14), T2DM (N=10), and HC (n = 11) *P-value < 0.05.FIGURE 2 | For identification of total ILCs, ILC1, ILC2, ILC3; PBMCs were stimulated and cultured for 6 hours with PMA/ionomycin plus Brefeldin A and stained for
surface markers. Size of groups: LTBI and T2DM (n = 13), LTBI (n = 14), T2DM (n = 10), and HC (n = 11). Data represent medians and interquartile ranges. The
non-parametric Kruskal-Wallis and Mann-Whitney U tests were used to determine the statistical significance between the medians. Differences were considered
statistically significant at P < 0.05 and 95% confidence level. Non-significant P-values were not shown.Frontiers in Immunology | www.frontiersin.org August 2021 | Volume 12 | Article 7168195
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differences in comparison to LTBI and T2DM and LTBI groups.
Relationship Between ILC Responses and
Glycaemic Levels Among T2DM Cases
HbA1c is an accurate indicator of the level of diabetic control
and increased values reflect poor control. Thus, to examine the
relationship between the ILC responses with the degree of
diabetic control, we used box plots to assess the association for
the frequencies of total ILC, ILC1, ILC2, ILC3, IFN-g, IL-13, and
IL-22, all measured using flow cytometry with HbA1c levels
(poor glycaemic control defined as HbA1c ≥7%, and good
glycaemic control as HbA1c <7%). We hypothesised that poor
glycaemic control further alters ILC responses. As shown in
Figure 4, poor glycaemic control had slightly higher total ILCs,
ILC1, ILC2, ILC3 and IFN-g responses while good glycaemic
control had slightly higher IL-13 and IL-22 responses.Frontiers in Immunology | www.frontiersin.org 6DISCUSSION
The underlying immunological mechanism for increased
tuberculosis in patients with T2DM remains to be more
elucidated. Research has shown that T2DM dysregulates
immune system components including changes in the number
and activation state of immune cell subsets, and altered cytokine
levels (40). This study aimed to understand the influence of
T2DM on ILC responses in subjects with latent TB infection,
with the hypothesis that T2DM alters ILC responses making
patients more susceptible to LTBI. ILC responses were variable
between the different study groups.
People with T2DM and LTBI had a marginal suppression of
immunity as demonstrated by the decreased total ILCs, ILC2 and
ILC3 frequencies (Figure 2), as well as reduced IFN-g and IL-13
cytokine production (Figure 3B). However, these differences were
not statistically supported. IL-22 cytokine production was howeverA
B
FIGURE 4 | Relationship between ILC responses and diabetes control (Poor and good glycaemic control). (A) Responses of total ILCs, ILC1, ILC2, ILC3 in poor
and good glycaemic control. (B) Responses of IFN-g, IL-13 and IL-22 in poor and good glycaemic control. Box plots show median values and 25th –75th percentiles
from data in each group with maximum and minimum values. Poor glycaemic control was defined as HbA1c levels ≥ 7.0%, and good glycaemic control was defined
as HbA1c levels <7%. The non-parametric Mann-Whitney U test was performed, and differences were considered statistically significant at P < 0.05 and 95%
confidence level. Non-significant P-values were not shown. Size of groups: LTBI and T2DM (n = 13), LTBI (n = 14), T2DM (N=10), and HC (n = 11).August 2021 | Volume 12 | Article 716819
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anticipated, ILC3 frequencies were slightly higher in the diabetics
than in any other study group since these are associated with poor
metabolic homeostasis, through the production of IL-17 (41), and
on a contrary to alleviate metabolic disorders in diabetes through
the production of IL-22 (42). However, in this study, we found very
low production of IL-22 by the ILC3s in T2DM. This is similar to a
study by Shen et al. (43) that reported IL-22 levels being
significantly lower in patients with T2DM compared to those
without T2DM. The prototypical type 17 cytokine, IL-22,
produced by ILC3s has been shown to play a central role in
mediating immunity to both extra and intracellular bacteria,
including Mtb (44). Ardain et al. (31) also reported that ILC3s
mediate early protective immunity against TB infection, and IL-22
production by ILC3s was critical for early innate immunity and
granuloma formation. Another study reported IL-22 production by
two ILC3 subsets, lymphoid tissue inducers (LTi) and natural
cytotoxicity receptor (NCR)+ ILC3s, to be significantly decreased
in Mtb-infected mice with T2DM than in Mtb-infected mice
without T2DM (45). The authors further demonstrated that Mtb-
infected T2DMmice had prolonged survival following recombinant
IL-22 treatment or adoptive ILC3 transfer (45). It is paradoxical to
have low IL-22 cytokine responses despite high ILC3 expression.
This is probably because ILC3s weren’t activated in response to any
of the disease states, or the type 17 cytokine, IL-17A was instead
produced, but it was not measured. It is also probable that T2DM
inhibited IL-22 cytokine production, mechanisms of which were not
assessed in this study.
Also of major importance is IFN-g, the functions of which are
well documented in both mouse models and human infections
(46, 47). IFN-g is a key Th-1 signature cytokine that is up-
regulated by Mtb infection, critical for tuberculosis control (48),
however, this may not translate into immune correlates of
protection against TB (49). Ardain et al. (31) reported that
blood ILC1s were depleted in participants with TB compared
to controls, and these rebounded after treatment, indicating that
TB influences blood ILC1 responses. They further demonstrated
that Lung ILC1s do not rapidly accumulate in the lung following
TB infection and that Ifng−/− mice maintained Mtb control.
Indeed, Sakai et al. (50) earlier showed that IFN-g responses are
only approximately 30% of the CD4 T cell cumulative Mtb
control, but over 80% in the spleen. Taken together, the data
shows that the role of ILC1-derived IFN-g may be in the blood
and extra-pulmonary sites. In T2DM, blood and adipose tissues
had elevated ILC1s and IFN-g compared to normal individuals
(36, 37). The authors further demonstrated that elevated
ILC1+IFN-g+ cells resulted in an increased risk of T2DM (36).
This shows that TB and T2DM independently modulate ILC
responses. Whether this applies to LTBI-T2DM comorbidity
remains to be assessed. In this study, patients with LTBI and
T2DM had a slightly higher production of IFN-g. This finding
may appear to be paradoxical because patients with T2DM are
more susceptible to LTBI. A possible explanation is that type 2
diabetic patients show changes in the downstream signal
transduction of key Th1 and innate immune response
cytokines, perhaps because of increased advanced glycationFrontiers in Immunology | www.frontiersin.org 7end products that bind and modify protein function (51). This
suppresses downstream responses important in eliminatingMtb,
despite high levels of protective cytokines. This possibly results
from the failure of cytokines to induce negative feedback
mechanisms, that normally control their expression or an
increased half-life of cytokines because of delayed proteolysis
resulting from binding of advanced glycation end products (52).
Therefore, probable that T2DM impairs the immune response in
LTBI, resulting in insufficient production of protective ILC1
responses, potentially increasing susceptibility to active TB
disease. Our data shows reduced ILC1 among individuals with
LTBI only. This could be as a result of the immune-modulating
effects of Mtb including preventing activation of pathogen
destruction systems (53), and blocking the presentation of
antigens on class II MHC by action on endosomal sorting
complexes required for transport (ESCRT) of its EsxG·EsxH
protein (53).
Obesity induces low-grade chronic inflammation in the white
adipose tissue (WAT) increasing the risk of metabolic disorders
(54, 55). Type 2 responses are associated with the recruitment of
alternatively activated macrophages (AAMs) that promote the
development of functional beige fat (56). ILC2s have been
identified to regulate eosinophil and AAMs recruitment
through the production of IL-5 and IL-13 (18), and to limit
obesity in mice and human WAT (19, 57). In these studies,
obesity in mice and humans is associated with decreased ILC2s
(19, 57). Ardain et al. (31) demonstrated that blood ILC2s to be
involved in the pathogenesis of TB. ILC2s are depleted during TB
infection despite being activated and accumulate in the lung
following TB infection (31). This remains to be assessed in a
metabolic disorder like obese associated-T2DM, and its effects on
LTBI in humans. In our study, we demonstrate that participants
with LTBI and T2DM had slightly lower ILC2 levels (Figure 2),
and IL-13 production compared to other groups (Figure 3B).
Indeed, T2DM participants had slightly lower ILC2 levels and IL-
13 production. This is consistent with studies of adaptive
immunity that demonstrate a decrease in Th2 cellular
responses in participants with LTBI-type 2DM compared to
LTBI without T2DM. Hence T2DM may be associated with a
general decrease in ILC2 responses. ILC2 production of type 2
cytokines that results in AAMs recruitment (19, 57) may be
considered detrimental in controlling Mtb. This may be
contradictory as Sudo et al. (58) reported that ILC2s produce
GM-CSF, a cytokine known to activate macrophages and control
Mtb infection (59). This may explain the slight increase in the
ILC2 and IL-13 levels in the LBTI group.
Immune responses are known to be altered in T2DM, with
hyperactivation of T-cells as a significant feature (60). Poor
glycaemic control is associated with poor infection control
(61), and elevated inflammatory activity (62). ILCs have been
implicated to be critically involved in the pathogenesis of chronic
inflammatory diseases including obesity and T2DM (35–38),
Crohn’s disease (63), multiple sclerosis (64) and psoriasis (65).
However, a direct relationship between ILC responses and
T2DM remains to be elucidated. Studies by Liu et al. (37) and
Wang et al. (36) reported a positive correlation between adiposeAugust 2021 | Volume 12 | Article 716819
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(FBG). In this study, we report that the association between
HbA1c levels and ILC immune responses indicate a general
minimal alteration of ILC immune responses in poor and good
glycaemic control (Figure 4). Poor glycaemic control had slightly
higher total ILCs, ILC1, ILC2, ILC3 and IFN-g responses but
slightly lower IL-13 and IL-22 responses. The further depressed
IL-22 with poor glycaemic control suggests more immune
suppression in T2DM and plausible susceptibility to
TB infection.
Humans show significant sex differences in the incidence and
severity of respiratory diseases, including asthma and virus
infection. Sex hormones (oestrogens and androgens) contribute to
the female sex bias in type 2 inflammation associated with
respiratory diseases, consistent with recent reports that female
lungs harbour greater numbers of GATA-3–dependent group 2
innate lymphoid cells (ILC2s) (66–68). In the current study, we
analysed ILC subsets and cytokine responses based on sex
differences to determine whether there are any ILC response
differences. There were no distinct differences in ILC responses
based on sex (Supplementary Figures 1A, B). Notably, no changes
in effector functions were found between male and female ILC2s
when stimulated with PMA/ionomycin, indicating a selective deficit
in IL2R- or ST-2-signaling pathways imprinted by androgen
signalling (66). In this study, PBMCs were stimulated with PMA/
Ionomycin, and this could explain the observations found.
The frequency and functional capacity of ILCs over the human
lifespan has been demonstrated. Darboe et al. (69) assessed the
numbers and frequencies of ILC subsets in peripheral blood in a
group of Gambians aged 5 to 73. The authors reported that ILC1
frequencies were stable whereas ILC3 absolute numbers and
frequency decreased steadily throughout life, as ILC2 absolute
numbers and frequency decreased from childhood until around
the age of 30 (69). In our study, we report that the frequency of ILC
subsets declined throughout life, with total ILC and ILC2
frequencies declining quite markedly (Supplementary
Figures 2A, B). Though not markedly, the decline of ILC1
frequency with age is in agreement with a study that reported a
decline of frequency and absolute counts of ILC-1 like cells with
gestational age (70). The authors further show that ILC2 and ILC3
frequencies declined markedly (70). This partially agrees with this
study that reported slight declines of ILC2 and ILC3 frequencies
respectively. Functionally, IFN-g markedly declined whereas IL-13
and IL-22 slightly declined with age, reflecting declining functional
attributes of ILC subsets with age. This may be attributable to
functional redundancy of CD4+ T cells and the ILC subset
counterparts (71). The divergent results in these studies may
reflect differences in study design.
There is evidence of plasticity (ILC3 to ILC1, and ILC2 to
ILC1) demonstrated in both humans and mice, producing IFN-g
in both conversions. However, ILC3 and ILC2 plasticity requires
inflammatory cytokines such as IL-23, IL-15, IL-12 and IL-1b.
ILC3 plasticity has been demonstrated in Crohn’s disease (72),
while ILC2 plasticity in COPD (73) and Crohn’s disease (74).
T2DM being a chronic inflammatory disease could change the
cytokine microenvironment affecting the conversions. This hasFrontiers in Immunology | www.frontiersin.org 8not been fully demonstrated in T2DM. Indeed, corral et al. (75),
(unpublished) demonstrated that ILC1-like-IFN-g producing
cells that expressed little to no classical ILC2 markers emerged
during Mtb infection. The authors further illustrated that
metabolic environment inhibits ILC2 while augmenting ILC1-
like- IFN-g producing cells (75). The current study did not assess
for the origin of ILC1 and IFN-g production, therefore did not
evaluate ILC2 and ILC3 plasticity.
This study suffered limitations of being descriptive, having a
small sample size, and measuring only percentages of ILC sub-
sets as opposed to absolute cell numbers. Also, the study did not
collect data on confounding variables such as helminth infection
or allergy status that may affect the ILC responses. This study was
able to show the effect of T2DM on ILC immune responses in
individuals with latent TB infection. It would be interesting to
study the impact of T2DM on ILC immune responses in
individuals with active TB, and the PTB-T2DM impact on
other pathogens.CONCLUSION
Our data imply that observed ILC sub-set immune alterations are
driven by chronic hyperglycaemia. It also supports the growing
body of evidence that confirms that immunodeficiency is an
integral part of T2DM and that this compromise could have
serious consequences in the face of intracellular pathogens that
require type-1 associated cytokines for resistance. This study
provides an impetus to perform longitudinal studies examining
the role of T2DM related immunosuppression in the progression
from latent infection to active tuberculosis in the face of innate
lymphoid cells. It is also a gap to further assess the transcription
factors and genes that are upregulated and downregulated by
innate lymphoid cells in LTBI-T2DM patients, and to study
lung tissues and determine whether the innate lymphoid cells
seen are either tissue-resident or circulating. Future studies could
further look at the dysregulation of the innate lymphoid cells
in patients having active tuberculosis and type 2 diabetes
mellitus, and assess the effects on treatment response of both
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